Ginkgo Bioworks is an analytics company that designs custom microbes for customers across multiple markets, developing new organisms that replace technology with biology.
Ginkgo Bioworks specializes in using genetic engineering to produce bacteria with industrial applications. It uses the most advanced technology on the planet – biology – to grow products instead of manufacturing them.
Ginkgo Bioworks was founded in 2009 by Tom Knight, Austin Che, Reshma P. Shetty, Barry Canton, Reshma Shetty, & Jason Kelly. The company is headquartered in Boston, Massachusetts.
Gingko Bioworks also provides probiotic bacteria to protect the body from dangerous infections, and it generates libraries of molecules. It serves cultured ingredients, carbon mitigation, probiotics, and natural product discovery markets.
Ginkgo Bioworks designs microbes in analytical labs it calls synthetic biology foundries, which comprise software and hardware tools that allow for rapid prototyping and high-throughput screening. Several publicly-stated products include chemical intermediates, flavors, and fragrances; as well as microbes that provide health benefits to the human gut microbiome and agricultural crop root microbiomes.
Ginkgo Bioworks has partnerships with Amyris, ADM, Bayer, Cargill, Genomatica, Prospect Bio, & Synlogic.
Ginkgo Bioworks' investors include T. Rowe Price,Bill Gates, Y Combinator, Felicis Ventures, Data Collective, Viking Global Investors, Baillie Gifford, & Cascade Investment among others. The company has raised $290M from a "Series E" financing on Sep 19, 2019. This brings Gingko's total funding to $719M to date.
Ginkgo has been valued at $4.2B from its latest "Series E" round on Sep 19, 2019. The company has also acquired Gen9 & Warp Drive Bio, as well as made over $370M investemnts to-date.